Baxter CDMO BioPharma Solutions names Franco Negron as CEO ahead of proposed sale
Baxter’s CDMO arm, BioPharma Solutions, has announced a new CEO will take the reins following its proposed sale to private equity company Advent International and investment outfit Warburg Pincus for $4 billion.
Advent and Warbug picked Novartis veteran Franco Negron to lead the charge. Negron has more than 30 years of experience in the manufacturing and pharma industry, and previously served as CEO of the medical technology company ApiJect and held leadership positions at contract manufacturer Patheon before Thermo Fisher acquired it in 2017. He also served at Valeant Pharmaceuticals.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.